Cyclosporine for Thrombotic Thrombocytopenic Purpura
Authors: Horst Kierdorf
Journal: Annals of Internal Medicine (1993)

Letters15 June 1993Cyclosporine for Thrombotic Thrombocytopenic PurpuraHorst Kierdorf, MD, Norbert Maurin, MD, and Bernhard Heintz, MDHorst Kierdorf, MDSearch for more papers by this author, Norbert Maurin, MDSearch for more papers by this author, and Bernhard Heintz, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-118-12-199306150-00022 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Thrombotic thrombocytopenic purpura consists of thrombocytopenia, microangiopathic hemolytic anemia, fluctuating neurologic signs, fever, and renal impairment [1]. The primary treatment modality is plasmapheresis, which is sometimes combined with antiplatelet therapy [2]. Splenectomy and immunosuppressive therapy have been used where the response is poor [2, 3].We describe a 64-year-old man in whom the disease was controlled by cyclosporine after plasmapheresis failed. When admitted, he was in a confused state and had an unexplained fever (temperature, 39.1 C), a slightly enlarged liver, a hemoglobin concentration of 97 g/L, a platelet count of 31 000/mm3, red cell fragmentation (25% ...References1. Bukowski RM. Thrombotic thrombocytopenic purpura. A review. Prog Hemost Thromb. 1982; 6:287-337. Google Scholar2. Welborn JL, Emrick P, Acevedo M. Rapid improvement of thrombotic thrombocytopenic purpura with vincristine and plasmapheresis. Am J Hematol. 1990; 35:18-21. Google Scholar3. Schmidt JL. Thrombotic thrombocytopenic purpura: Successful treatment unlocks etiologic secret. Mayo Clin Proc. 1989; 64:956-61. Google Scholar4. Rose M, Eldor A. High incidence of relapses in thrombotic thrombocytopenic purpura. Clinical study of 38 patients. Am J Med. 1987; 83:437-41. Google Scholar5. Moake JL, Rudy CK, Troll JH, et al. Von Willebrand factor abnormalities and endothelial cell perturbation in acute thrombotic thrombocytopenic purpura. Am J Med Sci. 1986; 291:47-50. Google Scholar Author, Article, and Disclosure InformationAuthors: Horst Kierdorf, MD; Norbert Maurin, MD; Bernhard Heintz, MD PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited bySuccessful preventive treatment with cyclosporine in a patient with relapsed/refractory immune-mediated thrombotic thrombocytopenic purpura: a case report and review of the literaturePredictors of relapse and preventative strategies in immune thrombotic thrombocytopenic purpuraCaplacizumab in adult patients with acquired thrombotic thrombocytopenic purpuraHow I treat refractory thrombotic thrombocytopenic purpuraCyclosporin A therapy on idiopathic thrombotic thrombocytopenic purpura in the relapse setting: two case reports and a review of the literatureInvestigational drugs in thrombotic thrombocytopenic purpuraTreatment of refractory thrombotic thrombocytopenic purpura using multimodality therapy including splenectomy and cyclosporineEffect of blood group on idiopathic thrombotic thrombocytopenic purpuraTargeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpuraSuccessful Treatment of Refractory Thrombotic Thrombocytopenic Purpura with Cyclosporine and Corticosteroids in a Patient with Systemic Lupus Erythematosus and Antibodies to ADAMTS13High Titer of ADAMTS13 Inhibitor Associated with Thrombotic Microangiopathy of the Gut and Skeletal Muscle after Allogeneic Hematopoietic Stem Cell TransplantationAn evaluation of cyclosporine alone for the treatment of early recurrences of thombotic thrombocytopenic purpuraImmunotherapy for thrombotic thrombocytopenic purpuraExcellent response of refractory life-threatening thrombotic thrombocytopenic purpura to cyclosporine treatmentPost-operative thrombotic thrombocytopenic purpura: A reviewOverweight individuals are at increased risk for thrombotic thrombocytopenic purpuraUse of Vincristine and Cyclosporine in Childhood Thrombotic Thrombocytopenic PurpuraLate Response to Cyclosporine in Refractory Thrombotic Thrombocytopenic PurpuraRefractory thrombotic thrombocytopenic purpura in a lupus nephritis patientvon Willebrand Factor Proteolysis Is Deficient in Classic, but not in Bone Marrow Transplantation–Associated, Thrombotic Thrombocytopenic Purpuravon Willebrand Factor Proteolysis Is Deficient in Classic, but not in Bone Marrow Transplantation–Associated, Thrombotic Thrombocytopenic PurpuraHemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura in the ICUSuccessful use of cyclosporine A in the treatment of refractory thrombotic thrombocytopenic purpuraChronic relapsing thrombotic thrombocytopenic purpura: Role of therapy with cyclosporineThrombotic thrombocytopenic purpura and hemolytic uremic syndrome in pregnancy: Review of 11 casesTHROMBOTIC MICROANGIOPATHIES ASSOCIATED WITH DRUGS AND BONE MARROW TRANSPLANTATIONRefractory thrombotic thrombocytopenic purpura treated with cyclosporineThrombotic Microangiopathic Syndromes After Bone Marrow TransplantationThrombotic Microangiopathy After Bone Marrow TransplantationHLA-DR53 protects against thrombotic thrombocytopenic purpura/adult hemolytic uremic syndrome 15 June 1993Volume 118, Issue 12Page: 987-988KeywordsCreatinineDehydrogenasesFeversHemoglobinImmunosuppressivesPlateletsSplenectomyTemperatureThrombotic thrombocytopenic purpuraUrea ePublished: 15 August 2000 Issue Published: 15 June 1993 Copyright & PermissionsCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...